Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04543357 · ClinicalTrials.gov registry record
A Study to Evaluate AAV9 Neutralizing Antibody Seroconversion in Household Contacts.
A clinical trial, sponsored by Pfizer.
- Terminated
- Registry status
- 8
- Enrollment target
NCT04543357 is a clinical trial that was terminated before completion, run by Pfizer. The registered enrollment target is 8 participants.
The verdict
NCT04543357 was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- 8 participants
- Enrollment target
Study Summary
This study will include male and female participants who live or work in the same household as a patient in one of the fordadistrogene movaparvovec interventional studies. Up to 5 participants from the same household may be enrolled. The objective is to estimate the likelihood of NAb seroconversion to AAV9 in household contacts of a patient in one of the interventional studies who is treated with fordadistrogene movaparvovec gene therapy.
Interventions
- OTHER Blood Draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-08-17 |
| Est. Completion | 2024-02-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04543357
The ClinicalTrials.gov registry entry for NCT04543357 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Blood Draw is the first listed.
NCT04543357 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04543357 about?
NCT04543357 is a clinical study titled "A Study to Evaluate AAV9 Neutralizing Antibody Seroconversion in Household Contacts.". This study will include male and female participants who live or work in the same household as a patient in one of the fordadistrogene movaparvovec interventional studies. Up to 5 participants from the same household may be enrolled. The objective is to estimate the likelihood of NAb seroconversion ...
What is the current status of trial NCT04543357?
This trial is currently terminated. The enrollment target is 8 participants. The study started on 2022-08-17. Estimated completion is 2024-02-27.
What interventions are being tested in trial NCT04543357?
The interventions under investigation include: Blood Draw (OTHER).
Who is sponsoring clinical trial NCT04543357?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.